The phCMV vectors are a family of versatile mammalian expression vectors that utilize a uniquely modified CMV promoter to produce the highest levels of transgene expression available (up to 10X the expression levels of other commercially-available CMV promoter-based vectors).

Three phCMV vectors are available for generating high-level stable and transient transgene expression in mammalian cells. The phCMV1 vector is designed for native protein expression, while the phCMV2 and phCMV3 vectors are designed for expression of HA fusion proteins. Such fusion proteins can be easily detected or purified using anti-HA antibodies or anti-HA coupled chromatography columns.

The primary advantage of the phCMV vectors is that they contain a highly optimized CMV promoter, which has been systematically modified to produce the highest levels of transgene expression available (up to 5x higher than other CMV promoter-based mammalian expression vectors). Second, the phCMV vectors offer the flexibility of native protein expression (phCMV1), N-terminal HA fusion protein expression (phCMV2), or C-terminal HA fusion protein expression (phCMV3). Third, the phCMV vectors are very small and ideal for transfection because of their dual-use kanamycin/neomycin resistance gene and simplified backbone. Forth, in conjuction with the combination kanamycin/neomycin gene, the rigorously engineered backbones of the phCMV vectors allow for a smaller vector, providing greater transfection efficiency, high plasmid yield in E. coli, and enhanced expression levels in vitro and in vivo.

The phCMV vectors are a family of versatile mammalian expression vectors that utilize a uniquely modified CMV promoter to produce the highest levels of transgene expression available (up to 10X the expression levels of other commercially-available CMV promoter-based vectors).

Three phCMV vectors are available for generating high-level stable and transient transgene expression in mammalian cells. The phCMV1 vector is designed for native protein expression, while the phCMV2 and phCMV3 vectors are designed for expression of HA fusion proteins. Such fusion proteins can be easily detected or purified using anti-HA antibodies or anti-HA coupled chromatography columns.

The primary advantage of the phCMV vectors is that they contain a highly optimized CMV promoter, which has been systematically modified to produce the highest levels of transgene expression available (up to 5x higher than other CMV promoter-based mammalian expression vectors). Second, the phCMV vectors offer the flexibility of native protein expression (phCMV1), N-terminal HA fusion protein expression (phCMV2), or C-terminal HA fusion protein expression (phCMV3). Third, the phCMV vectors are very small and ideal for transfection because of their dual-use kanamycin/neomycin resistance gene and simplified backbone. Forth, in conjuction with the combination kanamycin/neomycin gene, the rigorously engineered backbones of the phCMV vectors allow for a smaller vector, providing greater transfection efficiency, high plasmid yield in E. coli, and enhanced expression levels in vitro and in vivo.